Literature DB >> 16876821

Chimeric Fc receptors identify ligand binding regions in human glycoprotein VI.

Bénédicte Dumont1, Izida Minullina, Stéphane Loyau, Renato C Monteiro, Jean-Jacques Lacapere, Véronique Arocas, Martine Jandrot-Perrus.   

Abstract

Glycoprotein (GP) VI, a key receptor for collagen-induced platelet activation, recently emerged as a major target for developing new antithrombotics. However, little is known about its functional domains, which is a disadvantage for the rational development of antagonists. Our aim was to identify the structures determining GPVI specificity. GPVI presents homologies with members of the Ig superfamily (in particular with FcalphaRI) whose extracellular parts present two domains, D1 and D2 linked by a hinge interdomain. To identify the respective role of these domains in GPVI, we have substituted D1 and D2 by their FcalphaRI homologue in a soluble GPVI fusion protein (GPVI-Fc) and have modified the linker motif by mutagenesis. Proteins were tested for their binding to ligands and antibodies specific for GPVI and FcalphaRI. We demonstrate for the first time that D2 plays a specific and significant role in GPVI binding to collagen and that the hinge interdomain is critical for the binding to convulxin. Furthermore, binding to CRP requires elements of D1 and of the linker motif. Our results indicate that GPVI is unique amongst the receptors of its family as it uses different structural domains to interact with several agonists and provide evidence that different sites on GPVI constitute targets to develop antagonists of GPVI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876821     DOI: 10.1016/j.jmb.2006.06.053

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  2 in total

1.  A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex.

Authors:  Hiroshi Takayama; Yoshitaka Hosaka; Kazuyuki Nakayama; Kamon Shirakawa; Katsuki Naitoh; Tomokazu Matsusue; Mikihiko Shinozaki; Motoyasu Honda; Yukiko Yatagai; Tetsushi Kawahara; Jiro Hirose; Tooru Yokoyama; Michiru Kurihara; Shoji Furusako
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

2.  Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan.

Authors:  Peng Jiang; Stéphane Loyau; Maria Tchitchinadze; Jacques Ropers; Guillaume Jondeau; Martine Jandrot-Perrus
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.